证券代码：603882 证券简称：金域医学 公告编号：2025-001 广州金域医学检验集团股份有限公司 第四届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第 三次会议于 2025 年 1 月 13 日以通讯方式召开，会议通知已于 2025 年 1 月 7 日 以电子形式发出。会议由董事长梁耀铭先生主持，本次会议应出席董事 9 名，实 际出席董事 9 名。公司监事及高级管理人员列席本次会议。会议召开符合《中华 人民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 （二）审议通过《关于预计与广州金墁利医药科技有限公司 2025 年度日常 关联交易的议案》 经审议，董事会同意公司及下属企业预计 2025 年度与关联方广州金墁利医 药科技有限公司及其下属企业发生日常关联交易金额 13,250 万元。具体内容详 见公司同日于上海证券交易所网站（www.sse.com.cn）及公司指定披露媒体《中 国证券 ...

(一)股东会类型和届次 2025 年第一次临时股东会 证券代码：603882 证券简称：金域医学 公告编号：2025-005 广州金域医学检验集团股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 召开地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (五)网络投票的系统、起止日期和投票时间。 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 2 月 7 日 14 点 30 分 股东会召开日期：2025年2月7日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系统 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 关规定执行。 ( ...

Core Insights - The Guangzhou Data Exchange has launched its first medical testing data product for on-site trading, marking a significant step in the compliant trading of medical testing data in China [1][5][12] - The collaboration between KingMed Diagnostics and Shanghai Chenxi Technology Group aims to enhance the precision of medical resources and improve patient treatment through data empowerment [2][6][12] - KingMed Diagnostics has developed a range of data products, including a tuberculosis drug resistance map and a cervical cancer screening big data analysis report, which have passed compliance audits and are now available on the Guangzhou Data Exchange [2][3][11] Company Developments - KingMed Diagnostics has identified six major data resources, including respiratory pathogen targeted sequencing datasets, which have undergone initial property registration audits at the Guangzhou Data Exchange [3][7] - The company is actively collaborating with various organizations in disease monitoring, AI model training, and research projects, contributing to the innovation of the biopharmaceutical industry [4][10] - KingMed Diagnostics has publicly released its first data asset directory, encompassing over 3 billion testing data across various diseases, which supports comprehensive healthcare solutions [11] Industry Trends - The medical health data market in China is evolving towards a new era of "data elements × healthcare," with increasing recognition of the value of healthcare data and a shift towards data productization and standardized circulation [5][13] - The healthcare data market is projected to reach nearly 170 billion yuan by 2028, indicating significant growth potential in the sector [13] - The successful transaction of the first third-party medical testing data product represents a major breakthrough in the compliant circulation of medical testing data in China [12]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is a leading third-party medical testing service provider in China, with a significant market presence and a comprehensive range of testing services [6][21] - The company's revenue and profit growth have been under pressure due to lower-than-expected demand for routine testing and credit impairment losses [6][35] - The independent clinical laboratory (ICL) market in China has substantial growth potential, with a low penetration rate compared to developed countries [7][46] Company Overview - The company primarily engages in medical testing services and has established a vast network of laboratories and logistics to serve over 23,000 medical institutions across China [21] - From 2019 to 2023, the company achieved a compound annual growth rate (CAGR) of 13.54% in revenue, growing from 5.27 billion to 8.54 billion yuan [35] - The company's revenue for Q1-Q3 2024 was 5.62 billion yuan, reflecting a year-on-year decline of 10.95% due to reduced demand for COVID-19 testing and routine tests [35] Industry Overview - The ICL sector is characterized by technological, cost, efficiency, and standardization advantages, which are expected to enhance healthcare cost-effectiveness [7][42] - The penetration rate of ICL services in China is currently in the single digits, significantly lower than in Japan (60%), Germany (44%), and the USA (35%) [7][46] - The ongoing DRG payment reform and healthcare price adjustments are anticipated to drive hospitals to outsource more testing services, thereby increasing the market share of ICLs [7][47] Company Highlights - The company is expected to see improvements in accounts receivable collections due to government focus on resolving payment delays and ongoing economic stimulus policies [8] - Continuous innovation in product offerings is leading to an increase in revenue from high-end technology platform projects [8] - The company's digital transformation efforts are beginning to show results, including the launch of the first medical testing large model in the industry [8] Earnings Forecast and Investment Recommendations - The company is projected to achieve net profits of 204 million, 724 million, and 931 million yuan for 2024, 2025, and 2026, respectively, with corresponding earnings per share (EPS) of 0.44, 1.56, and 2.01 yuan [8] - The current stock price corresponds to a price-to-earnings (P/E) ratio of 77.82 for 2024, which is expected to decrease to 21.96 and 17.08 for 2025 and 2026, respectively [8]

Core Points - The company will cancel 5,513,000 shares that were repurchased, which will reduce the total share capital from 468,771,275 shares to 463,258,275 shares [2][3][5] - The cancellation of shares is scheduled for November 18, 2024 [3][6] - The total amount spent on the repurchased shares was approximately RMB 299.96 million [5] Group 1: Share Repurchase and Cancellation - The company has conducted four share repurchase programs, acquiring a total of 5,513,000 shares, representing 1.18% of the total share capital [5] - The purpose of the repurchased shares has changed from "for equity incentives" to "for cancellation and corresponding reduction of registered capital" [5][6] - The company has completed the necessary procedures for notifying creditors regarding the share cancellation, and no objections were raised [6] Group 2: Impact of Share Cancellation - The cancellation of the repurchased shares will not affect the controlling shareholder or actual controller of the company [8] - The company's debt repayment ability and ongoing operational capacity will remain unaffected [8] - The share distribution will still meet the listing requirements, ensuring the company's listing status is not compromised [8]

证券代码：603882 证券简称：金域医学 公告编号：2024-069 广州金域医学检验集团股份有限公司 关于注销已回购股份暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、回购股份注销审议情况 广州金域医学检验集团股份有限公司（以下简称"公司"）于2024年8月30 日及2024年9月27日分别召开第三届董事会第二十二次会议及2024年第二次临时 股东大会，分别审议通过了《关于变更回购股份用途并注销的议案》,具体内容 详见公司在上海证券交易所网站（www.sse.com.cn）及公司指定披露媒体《中国 证券报》、《上海证券报》、《证券日报》、《证券时报》于2024年8月31日披 露的《广州金域医学检验集团股份有限公司关于变更回购股份用途并注销的公告》 （公告编号：2024-053）及2024年9月28日披露的《广州金域医学检验集团股份 有限公司2024年第二次临时股东大会决议公告》（公告编号：2024-062）。 截至本公告披露日，公司共实施四次股份回购方案，合计通过集中竞价交易 方式回购 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [5]. Core Views - The company reported a revenue of 5.619 billion yuan for Q1-Q3 2024, a year-on-year decrease of 10.95%, with a net profit attributable to shareholders of 0.094 billion yuan, down 83.71% year-on-year [2]. - The decline in performance is attributed to external environmental changes, weak demand, and a high base in 2023, but improvements are expected as these pressures ease [2]. - The company's gross margin and net margin for Q1-Q3 2024 were 35.15% and 1.49%, respectively, both showing a decline compared to the previous year [2]. - The company has established a network of 49 medical laboratories across mainland China and Hong Kong, enhancing its competitive edge through cost leadership and digitalization [2]. - Cash flow has significantly improved, with accounts receivable decreasing to 5.121 billion yuan, indicating better collection efforts [2]. Financial Summary - For 2024, the company is expected to face significant external pressures, leading to a projected EPS of 0.42 yuan, with estimates for 2025 and 2026 at 1.42 yuan and 1.82 yuan, respectively [3]. - The report forecasts a recovery in revenue growth starting in 2025, with a projected revenue of 8.067 billion yuan in 2025, reflecting an 8.5% year-on-year increase [3]. - The company's net profit for 2024 is projected at 0.197 billion yuan, a decrease of 69.4% year-on-year, but expected to rebound to 0.668 billion yuan in 2025 [3]. - The report highlights a significant improvement in cash flow from operating activities, projected at 2.098 billion yuan for 2024 [6].

Investment Rating - The investment rating for the company is "Outperform the Market" [1][4][11] Core Views - The company experienced a 13% year-on-year decline in revenue in Q3 2024, primarily due to lower-than-expected growth in routine testing demand and high fixed costs leading to decreased operating leverage [1] - For the first three quarters of 2024, the company reported revenue of 5.619 billion (down 10.95%) and a net profit attributable to shareholders of 94 million (down 83.71%) [1] - The company is focusing on long-termism and innovation, having established 25 new precision medicine centers and 20 new academic and research collaborations in the first three quarters [1] - The gross margin improved in Q3 2024, reaching 36.0%, up 1.5 percentage points from the previous quarter, indicating enhanced management efficiency [1] - The company has improved its cash flow management, with net cash flow from operating activities reaching 312 million in the first three quarters, and 278 million in Q3 alone, representing an 80% year-on-year increase [1] Financial Summary - Revenue projections for 2024-2026 are adjusted to 7.849 billion, 8.658 billion, and 9.598 billion respectively, with year-on-year growth rates of -8.1%, 10.3%, and 10.9% [1][9] - The net profit attributable to shareholders is projected to be 230 million, 689 million, and 846 million for 2024-2026, with year-on-year growth rates of -64.3%, 200.1%, and 22.8% [1][9] - The current price-to-earnings (PE) ratio is 72.6 for 2024, 24.2 for 2025, and 19.7 for 2026 [1][9]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 44 yuan, while the current price is 34.72 yuan [1]. Core Insights - The company's revenue for the first three quarters of 2024 is 56.19 billion yuan, a decrease of 10.95% year-on-year, with a net profit attributable to shareholders of 0.94 billion yuan, down 83.71% [1]. - The accounts receivable collection has improved significantly, with a total impairment provision for accounts receivable of 4.20 billion yuan for the first three quarters of 2024, indicating a reduction in potential risks from COVID-related receivables [2]. - The company's conventional business is under pressure in the short term, with a 13.15% year-on-year decline in revenue for Q3 2024, primarily due to slower-than-expected growth in routine testing demand [2]. - Long-term core capability development is progressing steadily, with significant advancements in partnerships and operational management [2]. Financial Summary - Total revenue for 2023 is projected at 8.54 billion yuan, with a year-on-year decline of 44.8%. The forecast for 2024 is 7.62 billion yuan, a further decline of 10.8% [3]. - The net profit attributable to shareholders is expected to drop to 0.24 billion yuan in 2024, a decrease of 62.8% from 2023 [3]. - The company’s price-to-earnings (P/E) ratio is projected to be 68 in 2024, decreasing to 18 by 2026 [3].

Investment Rating - The report maintains a rating of "Buy" for the company [1][3]. Core Views - The company's performance has fallen short of expectations, but there is a significant improvement in cash flow. Short-term growth is under pressure, but the long-term outlook for outsourcing penetration is promising [1][8]. - The target price has been adjusted to 38.50 CNY, up from the previous forecast of 34.40 CNY, reflecting a revised EPS forecast for 2024-2026 [3][8]. Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 5.619 billion CNY, a decrease of 10.95% year-on-year. The net profit attributable to shareholders was 94 million CNY, down 83.71% [8]. - The gross margin for Q1-Q3 was 35.15%, a decline of 2.29 percentage points, while the net margin was 1.49%, down 7.49 percentage points [8]. - Cash flow management has improved significantly, with operating cash flow of 312 million CNY for Q1-Q3, and accounts receivable decreased by 214 million CNY from Q2 [8]. Industry Outlook - The industry is currently facing short-term challenges due to regulatory adjustments and policy implementations, which are expected to reduce testing volumes and lower prices. However, there is potential for increased outsourcing in the long term as hospitals seek to reduce costs [8]. - The company is focusing on quality growth and has established 25 new partnerships with precision medicine centers and 20 new collaborations in research and disease alliances during Q1-Q3 [8]. Digital Transformation - The company is advancing its digital transformation initiatives, enhancing management efficiency across marketing, supply chain, and services. It has launched four products on the Guangzhou Data Exchange, marking a step towards compliant medical data circulation [8].